Aegeline

Aegeline is a protoalkaloid compound found in Aegle marmelos (bael fruit) that primarily works through monoamine oxidase-A (MAO-A) inhibition and Akt pathway modulation. Research shows potential antidepressant, anti-inflammatory, and glucose metabolism effects, though evidence remains limited to preclinical studies.

Origin & History

Aegeline is a bioactive alkaloidal-amide compound isolated from the leaves and fruits of Aegle marmelos (Bael tree), native to India and Southeast Asia. It is extracted from plant materials using isolation techniques and characterized through NMR and mass spectrometry.

Historical & Cultural Context

While Aegle marmelos is used in Ayurvedic medicine, the research dossier provides no specific information about traditional or historical uses of aegeline itself. The compound's traditional applications remain undocumented in available sources.

Health Benefits

• May reduce depression-like symptoms through MAO-A inhibition (preclinical mouse studies only)
• Potential anti-inflammatory effects via IL-6 reduction and iNOS suppression (animal models)
• May improve glucose transport through Akt phosphorylation (in vitro studies)
• Possible neuroprotective effects against α-synuclein toxicity (yeast models)
• Could reduce oxidative stress by increasing glutathione levels (preliminary animal data)

How It Works

Aegeline inhibits monoamine oxidase-A (MAO-A) enzyme activity, which increases levels of neurotransmitters like serotonin and norepinephrine. The compound also activates Akt phosphorylation pathways, enhancing glucose transporter (GLUT4) translocation and cellular glucose uptake. Additionally, aegeline suppresses pro-inflammatory markers including interleukin-6 (IL-6) and inducible nitric oxide synthase (iNOS).

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on aegeline. All available evidence comes from preclinical studies including a reserpine-induced pain-depression mouse model (n=5 per group) where 10 mg/kg oral aegeline reduced MAO-A activity and inflammation markers (PMID: 33521442).

Clinical Summary

Current research on aegeline is limited to preclinical animal models and in vitro cell culture studies. Mouse studies demonstrated reduced depression-like behaviors in forced swim tests following aegeline administration. Anti-inflammatory effects were observed in rodent models with measurable reductions in IL-6 levels. No human clinical trials have been conducted to validate these preliminary findings or establish effective dosing protocols.

Nutritional Profile

Aegeline (N-[2-hydroxy-2-(4-methoxyphenyl)ethyl]-3-phenyl-2-propenamide) is a purified alkaloid compound, not a whole food ingredient, and thus has no conventional macronutrient or micronutrient profile. It is not a source of protein, carbohydrates, dietary fiber, fats, vitamins, or minerals. As a bioactive alkaloid, it is the sole relevant compound of interest. Aegeline is naturally found in the leaves of Aegle marmelos (bael tree) at trace concentrations estimated in the range of 0.01–0.1% dry weight of leaf extract, though precise standardized concentrations vary by extraction method. Molecularly, it has a MW of 299.37 g/mol and features a phenylpropanoid-cinnamate backbone with a methoxyphenyl ethanolamine moiety. Oral bioavailability data in humans is largely absent; preclinical pharmacokinetic data suggest moderate lipophilicity (logP approximately 2.5–3.0), which may facilitate passive membrane permeability, but first-pass metabolism and absolute bioavailability have not been formally characterized in human studies. Synthetic or semi-synthetic aegeline used in research and some supplement products is typically present at doses of 1–25 mg per serving. Notably, aegeline gained regulatory attention after being identified in OxyELITE Pro supplements linked to acute liver injury cases (2013 FDA investigation), underscoring that safety and bioavailability data at supplemental doses remain critically understudied in humans.

Preparation & Dosage

No clinically studied human dosages available. Preclinical studies used 10 mg/kg orally in mice for pain-depression models and 30-300 mg/kg for pharmacokinetic studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Antioxidants, MAO inhibitors, glucose support compounds, neuroprotectives, anti-inflammatories

Safety & Interactions

Safety data for aegeline supplementation in humans is currently unavailable due to lack of clinical studies. As a MAO-A inhibitor, aegeline may potentially interact with antidepressant medications, particularly SSRIs and MAOIs, creating risk for serotonin syndrome. Individuals taking diabetes medications should exercise caution due to potential glucose-lowering effects. Pregnant and breastfeeding women should avoid aegeline supplements due to insufficient safety data.